- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Eli Lilly raised Zepbound prices in the U.K. and plans to follow price hikes across Europe, while Novo Nordisk received a drug price reduction letter amid Trump administration pressure.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly introducing Mounjaro via the NHS and facing US pricing pressure from Trump.
Health Canada authorized the use of Eli Lilly's Mounjaro in Canada.
1 report, 1 independent
Updated Jul 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Health Canada authorized the use of Eli Lilly's Mounjaro in Canada.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Health Canada
Department of the Canadian Government that oversees public health
Related events
- The Food and Drug Administration approved Mounjaro, a drug developed by Eli Lilly and Company.
- Eli Lilly is seeking FDA approval for Zepbound and Mounjaro, tied to a $4 billion production site expansion in Kenosha, Wisconsin.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.
- Soutrik Banerjee is currently employed as a consultant at Eli Lilly and Company.